

## GHANA - Pneumococcal vaccine support

This decision letter sets out the programme terms of a programme.

- 1. Country: Ghana
- 2. Grant number: 1517-GHA-12c-X
- 3. Date of decision letter: 20 January 2016
- 4. Date of the partnership framework agreement: 11 July 2014
- 5. Programme title: New vaccine support (NVS), Pneumococcal Routine
- 6. Vaccine type: Pneumococcal
- 7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID
- 8. Programme duration<sup>1</sup>: 2012 -2017
- **9. Programme budget (indicative):** (subject to the terms of the partnership framework agreement)

	2012-2015	2016	2017	Total <sup>2</sup>
Programme budget (US\$)	US\$62,441,529 <sup>3</sup>	US\$6,444,000	US\$8,504,000	US\$77,389,529

- 10. Vaccine introduction grant (in US\$): . Not applicable
- **11. Indicative annual amounts:** (subject to the terms of the partnership framework agreement)<sup>4</sup>

Type of supplies to be purchased	2012-2015	2016
with Gavi funds in each year		
Number of Pneumococcal		1,227,600
vaccines doses		
Number of AD syringes		1,322,500
Number of re-constitution		
syringes		
Number of safety boxes		14,575
Annual amounts (US\$)	US\$62,441,529 <sup>5</sup>	US\$6,444,000

- **12. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.
- 13. Self-procurement: Not applicable.

<sup>&</sup>lt;sup>1</sup> This is the entire duration of the programme.

<sup>&</sup>lt;sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>&</sup>lt;sup>3</sup> This is the consolidated amount for all previous years.

<sup>&</sup>lt;sup>4</sup> This is the amount that Gavi has approved.

<sup>&</sup>lt;sup>5</sup> This is the consolidated amount for all previously approved years.



14. Co-financing obligations: Reference code: 1517-GHA-12c-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

-		
Type of supplies to be purchased	2016	2017
with Country funds in each year		
Number of vaccine doses	298,800	1,026,000
Number of AD syringes	321,100	
Number of safety boxes	3,550	
Value of vaccine doses (US\$)	US\$1,006,015	
Total co-financing payments (US\$)	US\$1,084,000	US\$3,562,500
(including freight)		

- 15. Operational support for campaigns: Not applicable
- **16. Additional reporting requirements:** The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

- 17. Financial clarifications: Not applicable.
- 18. Other conditions: Not applicable.

On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

bilast. K brill

20 January 2016